Melbourne, Australia; 16 October 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP^® irinotecan combination data poster, showcasing the recently announced¹ data for DEP^® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models. The data show that DEP® irinotecan in combination with an IO agent or a PARP² inhibitor demonstrated superior anti-tumour activity and significant survival benefit when compared to these agents delivered alone in multiple CRC models.

The poster was presented over the weekend in Boston, US, at the international oncology conference, International Conference on Molecular Targets and Cancer Therapeutics, co-hosted by the American Association of Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) from 11 to 15 October 2023.

This promising combination data, together with the recently released positive clinical results for DEP^® irinotecan, provide a strong rationale for clinical evaluation of DEP^® irinotecan with these leading classes of cancer drugs. These combinations are commercially important because they increase the potential market opportunities for DEP® irinotecan and illustrate valuable synergies with successful product categories.

The poster is appended.

View or download the ASX Announcement, here.

¹ ASX Announcement dated 27 September 2023: DEP^® irinotecan combination data presentation
² PARP: an enzyme called poly ADP ribose polymerase (PARP), which is involved in DNA repair.